Oxford Biomedica Regulatory News (OXB)

3 Feb 2005 10:51

Credit Agricole S.A.03 February 2005 FORM 8.1/8.3 Lodge with a RIS or Newstrack if appropriate and the Takeover Panel. Use aseparate form for each class of securities in which dealings have been made. Date of Disclosure03rd February 2005 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKEOVERSAND MERGERS Date of dealing02nd February 2005 Dealing in (name of company)Oxford Biomedica Plc (SEDOL 0664815) 1. Class of securities (eg ordinary shares)Ordinary 2. Amount Amount Price bought sold per unit 50,000 24.75 Part of our position is held in respect of hedges for CFDs (see below) 3. Resultant total of the same class owned or controlled (and percentage ofclass) 27,392,000 7.35 % 4. Party making disclosureCREDIT AGRICOLE SA (incl. the CALYON group of companies) 5. EITHER (a) Name of purchaser / vendor (Note 1)CHEUVREUX OR (b) if dealing for discretionary client(s), name of fund management organisation 6. Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) NO (ii) offeree company YES Specify which category or categories of associate (1-8 overleaf) 6 If category (8), explain (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of theclass of relevant securities dealt in) NO Signed, for and on behalf of the party named in (4) above Caroline Scott020 7214 5250 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identifycontroller of owner, eg where an owner normally acts on instructions of acontroller Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or with anassociate of any offeror or of the offeree company in relation to relevantsecurities, details of such arrangement must be disclosed, as required by Note 6on Rule 8. Note 5. It may be necessary, particularly when disclosing derivative transactions, toappend a sheet to this disclosure form so that all relevant information can begiven. Note 6. In the case of an average price bargain, each underlying trade should bedisclosed. Note 7. The resultant total percentage holding of the class of relevant security is tobe calculated by reference to the percentage held and in issue outside treasury. For full details of disclosure requirements, see Rule 8 of the Code. If indoubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No:020 7638 0129. Email: monitoring@disclosure.org.uk DEFINITION OF ASSOCIATE It is not practicable to define associate in terms which would cover all thedifferent relationships which may exist in an offer. The term associate isintended to cover all persons (whether or not acting in concert) who directly orindirectly own or deal in the shares of an offeror or the offeree company in anoffer and who have (in addition to their normal interests as shareholders) aninterest or potential interest, whether commercial, financial or personal, inthe outcome of the offer. Without prejudice to the generality of the foregoing, the term associate willnormally include the following:- (1) an offeror's or the offeree company's parent, subsidiaries and fellowsubsidiaries, and their associated companies, and companies of which suchcompanies are associated companies (for this purpose ownership or control of 20%or more of the equity share capital of a company is regarded as the test ofassociated company status); (2) banks and financial and other professional advisers (including stockbrokers)* to an offeror, the offeree company or any company covered in (1), includingpersons controlling#, controlled by or under the same control as such banks,financial and other professional advisers; (3) the directors (together with their close relatives and related trusts) of anofferor, the offeree company or any company covered in (1); (4) the pension funds of an offeror, the offeree company or any company coveredin (1); (5) any investment company, unit trust or other person whose investments anassociate manages on a discretionary basis, in respect of the relevantinvestment accounts; (6) a person who owns or controls 5% or more of any class of relevant securities(as defined in paragraphs (a) to (d) in Note 2 on Rule 8) issued by an offeroror an offeree company, including a person who as a result of any transactionowns or controls 5% or more. When two or more persons act pursuant to anagreement or understanding (formal or informal) to acquire or control suchsecurities, they will be deemed to be a single person for the purpose of thisparagraph. Such securities managed on a discretionary basis by an investmentmanagement group will, unless otherwise agreed by the Panel, also be deemed tobe those of a single person (see Note 8 on Rule 8); and (7) a company having a material trading arrangement with an offeror or theofferee company. Paragraphs (1)-(7) are typical cases. Paragraph (8) below is a category to coverassociate status not within (1)-(7). (8) Other. Notes * References to a "bank" do not apply to a bank whose sole relationship with aparty to an offer is the provision of normal commercial banking services orsuch activities in connection with the offer as confirming that cash isavailable, handling acceptances and other registration work. References to "financial and other professional advisers (includingstockbrokers)", in relation to a party to an offer, do not include anorganisation which has stood down, because of a conflict of interest orotherwise, from acting for that party in connection with the offer if theorganisation is to have a continuing involvement with that party during theoffer, the Panel must be consulted. Unless the Panel is satisfied that theinvolvement is entirely unconnected with the offer, the above exclusion will notnormally apply. # The normal test for whether a person is controlled by, controls or is underthe same control as another person will be by reference to the definition ofcontrol contained in the Code. There may be other circumstances which the Panelwill regard as giving rise to such a relationship (eg where a majority of theequity share capital is owned by another person who does not have a majority ofthe voting rights); in cases of doubt, the Panel should be consulted. Form 8 Enclosure Credit Agricole SA is now the beneficial owner of 27,392,000 Oxford BiomedicaPlc Ordinary shares. Credit Agricole Cheuvreux International holds a longposition of 27,392,000 shares held as a hedge for Contract for Differences ("CFD") positions for clients. A Long CFD is a product where the client to whom the product is sold is taking along economic interest in the underlying share price such that the client canrealise a gain if the price of the underlying securities rises above thereference price. A purchaser of a CFD contract will realise a gain if the price of the underlyingsecurity goes up. A seller of a CFD contract will realise a gain if the priceof the underlying security goes down. There are no written or oral agreements between Credit Agricole CheuvreuxInternational and any clients concerning the control of voting rights inrelation to the underlying shares used to hedge the CFDs. The CFD contracts areopen-ended. Contracts for DifferencesDisclosure Date: 28th January2005 Product Name Date Executed Buy / Sell Underlying Price Number of Shares (pence) Oxford Biomedica Plc, Long CFD 04/06/2004 Buy 100,000 19.2500 SNCOxford Biomedica Plc, Long CFD 08/06/2004 Buy 100,000 20.3750 SNCOxford Biomedica Plc, Long CFD 15/09/2004 Buy 15,752,000 15.2500 CACOxford Biomedica Plc, Long CFD 16/09/2004 Buy 100,000 17.2500 CACOxford Biomedica Plc, Long CFD 16/09/2004 Buy 250,000 15.5000 CACOxford Biomedica Plc, Long CFD 21/09/2004 Buy 6,800,000 17.2500 CACOxford Biomedica Plc, Long CFD 01/10/2004 Buy 50,000 17.2000 CACOxford Biomedica Plc, Long CFD 07/10/2004 Buy 100,000 19.7500 CACOxford Biomedica Plc, Long CFD 08/10/2004 Buy 200,000 20.3750 CACOxford Biomedica Plc, Long CFD 08/10/2004 Buy 50,000 20.1250 CACOxford Biomedica Plc, Long CFD 15/10/2004 Buy 100,000 20.2500 CACOxford Biomedica Plc, Long CFD 15/10/2004 Buy 100,000 20.5000 CACOxford Biomedica Plc, Long CFD 26/10/2004 Buy 100,000 19.0000 CACOxford Biomedica Plc, Long CFD 03/11/2004 Buy 50,000 20.5000 CACOxford Biomedica Plc, Long CFD 19/11/2004 Buy 100,000 17.7500 CACOxford Biomedica Plc, Long CFD 22/11/2004 Buy 100,000 17.7500 CACOxford Biomedica Plc, Long CFD 24/11/2004 Buy 100,000 17.5000 CACOxford Biomedica Plc, Long CFD 07/12/2004 Buy 100,000 18.0000 SNCOxford Biomedica Plc, Long CFD 13/12/2004 Buy 200,000 19.3100 CACOxford Biomedica Plc, Long CFD 19/01/2005 Buy 100,000 23.0000 CACOxford Biomedica Plc, Long CFD 24/01/2005 Buy 100,000 22.5000 CACOxford Biomedica Plc, Long CFD 25/01/2005 Buy 100,000 23.5000 SNCOxford Biomedica Plc, Long CFD 26/01/2005 Buy 800,000 24.0000 SNCOxford Biomedica Plc, Long CFD 26/01/2005 Buy 300,000 24.5000 SNCOxford Biomedica Plc, Long CFD 27/01/2005 Buy 900,000 25.8700 SNCOxford Biomedica Plc, Long CFD 27/01/2005 Buy 50,000 27.5000 CACOxford Biomedica Plc, Long CFD 27/01/2005 Buy 90,000 25.25 SNCOxford Biomedica Plc, Long CFD 31/01/2005 Buy 250,000 26.5 SNCOxford Biomedica Plc, Long CFD 01/02/2005 Buy 100,000 24.5 CACOxford Biomedica Plc, Long CFD 01/02/2005 Buy 100,000 24.5 CACOxford Biomedica Plc, Long CFD 02/02/05 Buy 50,000 24.75 CAC 27,392,000 CFDs Closed Out Product Name Date Executed Buy / Sell Underlying Open Price Close Number of Shares (pence) Price (pence)None This information is provided by RNS The company news service from the London Stock Exchange